Neuroactive steroid–serotonergic interaction: responses to an intravenous L-tryptophan challenge in women with premenstrual syndrome

Natalie Rasgon, Mariangela Serra, Giovanni Biggio, Maria Giuseppina Pisu, Lynn Fairbanks, Sahra Tanavoli and Andrea Rapkin

Departments of Psychiatry and Biobehavioral Sciences, Neuropsychiatric Institute and Obstetrics and Gynecology, UCLA School of Medicine, Los Angeles, California 90095, USA and Department of Experimental Biology, University of Cagliari, Italy

Abstract

Objective: To evaluate the circulating concentrations of the neuroactive steroids in response to an i.v. L-tryptophan (L-TP) challenge across the menstrual cycle in women with premenstrual syndrome (PMS) and in controls.

Method: An i.v. L-TP challenge was administered eight times during 1 month to five women with prospectively documented PMS and five age- and body mass-matched controls. Progesterone, allopregnanolone, pregnenolone and 3α-5α-tetrahydrocorticosterone were assessed 15 and 0 min before, and at 30, 60 and 90 min after the challenge, across the menstrual cycle.

Results: In response to L-TP challenge, only allopregnanolone concentrations were significantly increased across the cycle and this increase was of a greater magnitude in women with PMS. Pregnenolone and 3α-5α-tetrahydrocorticosterone concentrations were not affected in women with PMS or controls after L-TP challenge.

Conclusions: The data provide evidence for possible interaction between the serotonergic system and the neuroactive steroid, allopregnanolone. Women with PMS demonstrated a more significant increase in allopregnanolone concentrations in response to L-TP challenge, which could be due to an initial low basal serotonergic tone in the luteal phase in the PMS group.

European Journal of Endocrinology 145 25–33

Introduction

Serotonergic dysfunction as a potential cause of premenstrual syndrome (PMS) has been postulated on the basis of decreased concentrations of whole-blood serotonin and diminished platelet uptake of serotonin (1, 2). This concept has been supported by studies demonstrating the effectiveness of selective serotonin reuptake inhibitors (SSRIs) in the treatment of premenstrual dysphoric disorder (PMDD), a severe form of PMS (3, 4). It has been speculated that SSRIs ameliorate PMS symptoms by increasing the central serotonergic tone. However, the exact mechanism is still not known, as the anxiolytic effect of SSRIs in premenstrual syndrome cannot be fully explained on the basis of augmented serotonergic transmission alone (5). As the symptoms of PMS are maximal in the late luteal phase, it has been postulated that allopregnanolone, a neuroactive anxiolytic metabolite of progesterone, may be decreased in women with PMS and might account for some of the symptoms of PMS, in particular the irritability, anxiety and tension associated with the syndrome (6, 7). In both animal and clinical studies it has been demonstrated that neuroactive steroids display anxiolytic, anticonvulsant and mood stabilizing effects (8–12). Behavioral effects of neuroactive steroids are mainly determined by their modulation of the γ-aminobutyric acid (GABA A) receptor complex. Progesterone, the progesterone metabolite 3α-5α-tetrahydroprogesterone (allopregnanolone), and the 11-deoxycorticosterone metabolite 3α-5α-tetrahydrocorticosterone (THDOC) are positive allosteric modulators of the GABA A receptor, whereas pregnenolone sulfate is a negative allosteric GABA A receptor modulator (9). These neuroactive steroids are produced in the periphery (ovary, adrenals) and de novo in the brain (neurosteroids) either from cholesterol or through metabolism of blood-borne precursors (10).

It has been suggested that some of the effects of SSRIs on mood and seizure threshold could result from increased allopregnanolone production. Recent studies have suggested that the administration of SSRIs
increase allopregnanolone concentrations most probably as a result of a direct effect on the enzyme 3α-hydroxysteroid oxidoreductase, one of the two enzymes involved in the conversion of progesterone to allopregnanolone (13, 14).

The present study was therefore undertaken to assess whether alterations in central serotonergic tone modulate, by some mechanism, the circulating concentration of allopregnanolone in addition to the progesterone precursor pregnenolone in women with PMS. This was indirectly assessed by evaluating the plasma allopregnanolone and pregnenolone concentrations before and after the administration of l-tryptophan (l-TP), a precursor of serotonin that readily crosses the blood–brain barrier.

We evaluated allopregnanolone and pregnenolone concentration before and after l-TP challenge, twice per week for 1 month in women with prospectively documented PMS, and in controls. THDOC is predominantly an adrenal-derived metabolite of progesterone and corticosterone which has been shown to increase in the brain and plasma after stress (15–17). The pre- and post-challenge concentrations of THDOC were therefore also assessed in order to determine whether the changes, if any, in neuroactive steroids were specifically modulated by l-TP or were due to an increased response caused by stress.

Methods

Selection of participants

Women were recruited through advertisements in local newspapers. The study was approved by the Human Subject Protection Committee at the University of California, Los Angeles. All gave informed consent their participation. All prospective participants were evaluated for 2 months before acceptance into the study. During evaluation, the women were required to complete a daily symptom diary (18). This premenstrual diary consists of 11 of the more commonly experienced symptoms of PMS, including depression, anxiety, mood swings, irritability or anger, headaches, breast pain, low energy, edema, food cravings, avoidance of social activity, impaired relationships, and diminished work performance. Each symptom was rated on a scale of 1 (not at all) to 6 (extreme).

Eligibility criteria for the PMS group included: age 18–40 years, history of regular menses with moderate to severe premenstrual symptoms lasting for at least 1 week before menses occurring for at least the previous 6 months, negative medical history and no use of hormonal preparations including oral contraceptives for at least 6 months before enrollment into the study. All women were screened for the absence of significant medical illness (current or in the past 2 years) through history and physical examination. The body mass index (BMI) for all participants was calculated as the weight in kilograms divided by the square of the height in meters. Women with a BMI exceeding 25 were excluded.

All the women were administered a comprehensive psychiatric evaluation, the Structured Clinical Interview for DSM-IV (19), in the follicular phase of the menstrual cycle to confirm the absence of significant current or recent (past 2 years) major psychiatric illness including substance and alcohol abuse. Those with PMS who failed to demonstrate moderate to severe symptom scores on the daily diary with at least a 50% increase in a minimum of five symptoms including one psychological symptom between the follicular and luteal phases were excluded. Women accepted for study were required to meet the DSM-IV criteria for premenstrual dysphoric disorder. None of the women recruited into the study was receiving psychoactive medications, hormonal preparations (including oral contraceptives and thyroid replacement), mineral supplements or vitamins within the 3 months before or during the study. Eligibility criteria for controls were the same, except that premenstrual symptoms were absent. Once accepted into the study, all the women were required to complete the symptom diary for the ensuing 1 month of the study.

Procedure

The duration of the challenge study was 1 month. All women were required to abstain from alcohol and to follow a tyramine-free diet for 2 weeks before the challenge phase and throughout the study. All were required to abstain from food intake for the 12 h preceding the test.

Participants were required to present to the Clinical Research Center (CRC) at the UCLA Medical Center twice a week for four consecutive weeks. They began the month-long study within a few days of signing a consent form, irrespective of the day of their last menstrual period and were encouraged to keep their visits on the same day of the week (e.g. Thursday–Sunday, Tuesday–Friday etc.), to eliminate fluctuations in the schedule.

Because actual visits to the CRC were not timed to the particular phase of the menstrual cycle data were transformed according to the idealized 28-day menstrual cycle. The day of luteinizing hormone (LH) surge as determined by urinary LH detection test was considered as day 0. The follicular phase (inclusive of mid-to-late follicular phases) was considered as ovulation days −12 to −5, the ovulatory phase was calculated as ovulation days −4 to +3, and the luteal phase (inclusive of mid-to-late luteal phases) was calculated as ovulation days +7 to +14. The phase of the menstrual cycle in which blood was obtained was confirmed retrospectively by the date of onset of the next menstrual period.
Seventy-five women were screened for the study: 28 with premenstrual syndrome and 47 control individuals. Of the 28 women with premenstrual symptomatology, 18 were excluded for one or more of the following reasons: fear of venepuncture, lack of time, unwillingness to comply with diet and alcohol restrictions for the 6-week period, premenstrual exacerbation of underlying mood and anxiety disorder, or comorbidity with substance abuse. Three women moved out of the area at the time of the beginning of the challenge phase, and one patient developed fever at the time of the first CRC visit. Of the 47 controls, 22 rejected the study because of time constraints or fear of venepuncture, seven women had irregular menses, three had a psychiatric condition other than PMS, six women did not agree to use non-steroidal contraception, and one woman had an anovulatory cycle. After the above exclusions, six women with PMS and seven controls entered the challenge phase of the study. One woman with PMS and two controls withdrew from the study after the first visit secondary to lack of interest, thus five subjects in each group completed the study.

**Neuroendocrine challenge**

L-Tryptophan challenge was conducted as described by Price et al. (20). On the test day all women arrived at the CRC at 0700 h after an overnight fast and remained fasting until the end of the test. Beginning at 0700 h, the women rested on their beds supine with their heads slightly elevated, until the completion of the test (approximately 4 h later). They were allowed to ambulate to the bathroom, but not permitted to sleep. At 0730 h an i.v. catheter was placed in the forearm vein and was kept open with a flush of heparin. At 0900 h the women received an i.v. solution of L-TP (Arginomoto USA, Inc.) (7.0 g tryptophan diluted in 500 ml 0.47% normal saline) given at a constant rate for a 20-min period. At the same time, while the women were in a sitting position, pulse and blood pressure were measured in the usual clinical fashion. Samples were placed in EDTA-treated tubes at 15 min before and just before (time 0) the start of the tryptophan infusion, and at 30, 60 and 90 min after the start of the infusion.

**Biochemical methods**

The L-TP infusions were prepared by dissolving 8.4 g L-TP in 600 ml 0.45% saline solution, with 50% sodium hydroxide added to bring the solution to pH 7.4. Each 600-ml aliquot was sterilized by a passage through a 0.22-mm filter (Millipore) and was tested for pyrogenicity and sterility before use. Plasma samples were frozen and kept at −70 °C until required for assay.

**Extraction and assay of steroids**

The plasma samples (1 ml) were diluted with 2 ml water and then extracted three times with 3 ml ethyl acetate and the combined organic phases were dried under vacuum. The residue was dissolved in 3 ml n-hexane (70%) and propanol (30%). Steroids were quantified by RIA as previously described by Purdy et al. (15), with specific antibodies to pregnenolone and progesterone (ICN, Costa Mesa, CA, USA). Antibodies to allotetrahydroxycorticosterone (THDOC) and allopregnanolone were raised in rabbits and sheep and characterized as previously described (15). All measured variables were expressed in ng/ml. The limit of detection of the RIAs expressed as the minimal amount of steroids distinguishable from the zero sample was 0.01 ng and the intra- and interassay coefficients of variation ranged between 5 and 7% and between 9 and 11% respectively.

**Statistical analysis**

Diary data were evaluated by non-parametric statistics using the Mann–Whitney U test (21). The progesterone, pregnenolone, allopregnanolone, and THDOC responses to L-TP challenge were assessed during the follicular, ovulatory and luteal phases of the menstrual cycle. Pre-challenge concentrations were measured and the maximum (delta) change in concentrations of each variable was calculated by subtracting the mean pre-challenge value from the peak value observed at one of the 30–90 min time points in each cycle phase for each woman. The effects of PMS diagnosis on neurosteroid concentrations and delta concentrations were then assessed using multivariate analysis of variance with diagnostic group (PMS/control) as a between-group factor and cycle phase (follicular/ovulatory/luteal) as a within-individual factor. Cycle-phase effects were assessed for linear and quadratic components. Missing values for one cycle phase were replaced by the group mean for two individuals. For patients with more than one test in a given cycle phase, data were averaged to provide one score per woman per cycle phase. A square-root transformation was applied to correct for violation of independence of means and variances for the allopregnanolone change scores. Five women with PMS and four controls had complete data for progesterone, pregnenolone, allopregnanolone and THDOC.

All results are reported as significant when *P* was less than or equal to 0.05.

**Results**

**Characteristics of the participants**

The age range was from 20–35 years for both groups. Mean age for women with PMS was 24.4 ± 0.99 years...
and for controls it was 27.0 ± 6.7 years. All study participants were unmarried and nulliparous. There were no significant differences in the mean ages or BMI between groups. All women reported regular menstrual cycles ranging from 23 to 33 days in duration, and all ovulated as determined by the urinary LH detection kits.

Table 1 shows the mean symptom scores for the PMS and control groups during the follicular (ovulation days −12 to −5) and luteal (ovulation days +7 to +14) phases. Luteal phase symptoms scores in the PMS group were significantly greater than those in controls for most symptoms (Table 1). None of these comparisons differed significantly in the follicular phase.

### Table 1

<table>
<thead>
<tr>
<th>Symptom</th>
<th>PMS group</th>
<th>Control group</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Follicular</td>
<td>Luteal</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Follicular Luteal</td>
</tr>
<tr>
<td>Avoid social activity</td>
<td>1.4±0.8</td>
<td>2.8±1.5</td>
</tr>
<tr>
<td></td>
<td>(1.0–2.8)</td>
<td>(1.8–5.0)*</td>
</tr>
<tr>
<td>Decreased interest</td>
<td>1.6±1.0</td>
<td>3.1±1.5</td>
</tr>
<tr>
<td></td>
<td>(1.0–3.4)</td>
<td>(1.6–5.0)*</td>
</tr>
<tr>
<td>Edema/weight gain</td>
<td>1.2±0.3</td>
<td>3.6±1.1</td>
</tr>
<tr>
<td></td>
<td>(1.0–1.6)</td>
<td>(2.6–5.0)*</td>
</tr>
<tr>
<td>Depression</td>
<td>1.7±1.0</td>
<td>3.2±1.4</td>
</tr>
<tr>
<td></td>
<td>(1.0–3.4)</td>
<td>(1.8–5.2)**</td>
</tr>
<tr>
<td>Anxiety</td>
<td>1.7±1.6</td>
<td>2.8±1.4</td>
</tr>
<tr>
<td></td>
<td>(1.0–4.6)</td>
<td>(1.2–4.4)**</td>
</tr>
<tr>
<td>Mood swings</td>
<td>1.6±0.9</td>
<td>3.2±1.3</td>
</tr>
<tr>
<td></td>
<td>(1.0–3.0)</td>
<td>(1.8–4.6)**</td>
</tr>
<tr>
<td>Irritability</td>
<td>1.4±0.9</td>
<td>3.0±1.4</td>
</tr>
<tr>
<td></td>
<td>(1.0–2.4)</td>
<td>(1.4–4.8)**</td>
</tr>
<tr>
<td>Increased appetite/cravings</td>
<td>1.3±0.5</td>
<td>3.5±1.2</td>
</tr>
<tr>
<td></td>
<td>(1.0–2.2)</td>
<td>(1.8–5.0)*</td>
</tr>
<tr>
<td>Low energy/fatigue</td>
<td>2.2±1.7</td>
<td>3.2±1.2</td>
</tr>
<tr>
<td></td>
<td>(1.0–4.6)</td>
<td>(2.0–5.0)**</td>
</tr>
<tr>
<td>Headaches</td>
<td>1.8±1.7</td>
<td>2.5±1.3</td>
</tr>
<tr>
<td></td>
<td>(1.0–4.8)</td>
<td>(1.0–4.2)*</td>
</tr>
<tr>
<td>Breast pain</td>
<td>1.1±0.1</td>
<td>2.6±1.5</td>
</tr>
<tr>
<td></td>
<td>(1.0–1.2)</td>
<td>(1.0–4.4)</td>
</tr>
<tr>
<td>Sleep disturbance</td>
<td>1.5±0.5</td>
<td>2.1±1.2</td>
</tr>
<tr>
<td></td>
<td>(1.0–2.0)</td>
<td>(1.0–3.8)</td>
</tr>
<tr>
<td>Difficulty concentrating</td>
<td>1.6±1.4</td>
<td>3.0±1.6</td>
</tr>
<tr>
<td></td>
<td>(1.0–4.2)</td>
<td>(1.0–5.0)</td>
</tr>
</tbody>
</table>

*P < 0.05, **P < 0.01, PMS compared with control group.

**Hormonal variables**

**Pre-challenge hormonal changes** As all the women started the L-TP infusion in the follicular phase, the
ovulatory and luteal phase pre-challenge samples in these phases cannot be considered 'basal', because the prior L-TP infusions may have influenced the pre-challenge concentrations of neuroactive steroids. As expected, pre-challenge progesterone, pregnenolone and allopregnanolone concentrations increased from the follicular to the ovulatory to the luteal phase both in women with PMS and in controls. Figure 1 shows the mean (± s.e.) concentrations of progesterone, allopregnanolone, pregnenolone and THDOC by cycle phase for women with PMS and controls. There were significant interactions between group and cycle phase in the analyses of variance for each of the four steroids (progesterone: F = 5.70, P < 0.05; allopregnanolone: F = 4.15, P = 0.05; pregnenolone: F = 8.32, P < 0.05; THDOC: F = 6.77, P < 0.05). This indicates that women with PMS differ from normal controls in the pattern of change in neuroactive steroids over the menstrual cycle.

Allopregnanolone concentrations increased only slightly across cycle phases for the controls (4.85 ± 3.2 compared with 5.0 ± 2.3 and 6.7 ± 3.2 ng/ml), but more than doubled from the follicular (4.9 ± 2.0 ng/ml) to the ovulatory (10.8 ± 6.6 ng/ml) and luteal phases (11.7 ± 3.8 ng/ml) for those with PMS. The increase in allopregnanolone from the follicular to the luteal phase was statistically significant for the PMS group (paired t = 4.23, P = 0.01) but not for the controls.

Similar to allopregnanolone, pre-challenge concentrations of pregnenolone remained relatively constant throughout the cycle for the control group (3.44 ± 2.6 compared with 2.75 ± 2.3 and 3.46 ± 2.0 ng/ml) from the follicular to the ovulatory and luteal phases. In contrast, in women with PMS a significant increase was found in the pre-challenge pregnenolone concentrations from follicular to the luteal phase of the menstrual cycle (2.71 ± 0.73 compared with 4.89 ± 1.13 and 5.12 ± 1.14 ng/ml; paired t = 3.61, P < 0.05).

THDOC did not change throughout the menstrual cycle for the control group (1.45 ± 0.88 compared with 1.25 ± 0.75 and 1.35 ± 0.69 ng/ml), but increased across the cycle in the PMS group (Fig. 1). Pre-challenge THDOC concentrations increased by approximately 50% from the follicular (1.34 ± 0.60 ng/ml) to the luteal (1.96 ± 0.56 ng/ml) phases for the women with PMS (paired t = 5.28, P < 0.01).

Response to L-TP challenge
Figure 2 shows the mean (± s.e.) change in allopregnanolone, pregnenolone and THDOC concentrations after L-TP challenge for women with PMS and controls. The PMS group had a greater increase in allopregnanolone in response to the

![Graphs showing changes in allopregnanolone, pregnenolone, and THDOC](https://www.eje.org)
challenge compared with the control group, particularly during the luteal phase (PMS compared with control: \( F = 5.53, P = 0.05 \); group by cycle phase interaction: \( F = 5.79, P < 0.05 \)). These differences were not observed in either the delta pregnenolone or THDOCC responses following \( \tau \)-TP challenge (Fig. 2).

**Discussion**

Although numerous hypotheses have been advanced to explain the etiology of PMS, the cause of the syndrome is still unknown. We have previously demonstrated that whole-blood serotonin is decreased in the luteal phase in women with PMS compared with controls (1). On this basis, we speculated that the decrease in whole-blood serotonin may potentially reflect a decrease in serotonin concentration in the brain and may thereby lead to a decrease in central serotonergic activity, which may account for some of the symptoms of PMS. Subsequently other investigators have demonstrated decreased platelet uptake of serotonin in women with PMS (2) and there are numerous reports that administration of SSRIs and other serotonergic agonists leads to improvement in the symptoms of PMS/PMDD (3, 4, 22, 23). More recently, a relationship between the administration of SSRIs and the concentration of the neurosteroid allopregnanolone in human plasma and cerebrospinal fluid (CSF), and in rat brain sections (13, 24–26) have been reported. Allopregnanolone is a positive allosteric modulator of the GABA\(_A\) receptor and it has been demonstrated by some (6, 7), but not by others (27–29), that a luteal phase decrease in plasma allopregnanolone concentration is associated with PMS. Others reports have suggested that there is a decrease in the GABAergic sensitivity to neurosteroid administration in the luteal phase in women with PMS compared with controls (30, 31). Moreover, other receptors coupled to ion channels such as glycine receptors, nicotine acetylcholine receptors and 5-hydroxytryptamine 3 receptors have been identified as potential target for a modulation by various neuroactive steroids (32).

The primary objective of the present study therefore, was to assess whether i.v. challenge with the serotonergic precursor \( \tau \)-TP led to an increase in peripherally measured neuroactive steroid concentrations, with specific focus on allopregnanolone. We also wanted to assess whether the changes in allopregnanolone concentrations after \( \tau \)-TP challenge were different in women with PMS than in controls. As expected, we observed an increase in pre-challenge progesterone and allopregnanolone concentrations in the luteal phase compared with the follicular phase both in women with PMS and controls. In this respect our findings are consistent with those of other studies (27, 28, 33), indicating that changes in progesterone concentrations, which are greater in the luteal phase, and peripheral allopregnanolone concentrations parallel each other. In a previous study we had reported that, in the luteal phase, basal allopregnanolone concentrations were lower in women with PMS than in controls. In this study, as \( \tau \)-TP infusion was started randomly during the cycle, the luteal phase concentrations of allopregnanolone and other measured neuroactive steroids cannot be considered to be basal values as, on retrospective analysis, these women had already received \( \tau \)-TP infusion on at least three prior occasions, and two reported symptom improvement in the luteal phase of the challenge month. Alternatively, women with PMS may have been more stressed than controls, and allopregnanolone is known to increase after stress (15, 16). Higher levels of perceived stress and physiological arousal in women with PMS has been shown in response to activities of daily living and experimental stress paradigms (34–36). The greater luteal phase pre-challenge concentrations of THDOCC in the PMS group compared with that in controls also suggest that the PMS patients may have been more stressed at the time of the pre-challenge plasma sampling.

The main finding in this study was that, after \( \tau \)-TP challenge, circulating allopregnanolone concentrations were significantly increased in both controls and women with PMS during the luteal phase compared with the follicular phase of the menstrual cycle. As peripheral allopregnanolone concentrations parallel the progesterone concentrations, it is not surprising that, after \( \tau \)-TP challenge, allopregnanolone concentrations increased significantly only in the luteal phase when its substrate progesterone was also increased.

This increase in allopregnanolone concentrations in the luteal phase after the administration of \( \tau \)-TP in both controls and women with PMS strongly suggest that there is a relationship between central serotonergic activity and circulating allopregnanolone concentrations. The greater increase in allopregnanolone concentrations after administration of \( \tau \)-TP in women with PMS compared with controls most probably reflects the lower baseline serotonergic activity in this group of women, as has been suggested by us and others (1, 2, 37, 38). Therefore any mechanism by which central serotonergic activity is increased, as with the administration of \( \tau \)-TP in our study, or after administration of SSRIs – especially if the baseline central serotonergic activity is low – is likely to increase allopregnanolone concentrations to a greater degree than when the central serotonergic activity is high. This may potentially explain and, at least in part, account for some of the benefit observed in women with PMS treated with serotonergic agonists such as SSRIs, \( \tau \)-TP, fenfluramine and serotonergic tricyclic antidepressants (3, 4, 22, 23, 37, 39).

Another plausible explanation for the greater concentrations of the anxiolytic neurosteroid allopregnanolone, both before and after \( \tau \)-TP challenge in the setting of PMS symptomatology, is a reduced
GABAergic sensitivity in women with PMS. Several in vitro studies have demonstrated that even after short-term exposure to neurosteroids, cultured hippocampal and cortical cells manifest decreased GABAergic sensitivity to allopregnanolone (40). This effect may be more pronounced in women with PMS. Sundstrom et al. (41) noted that women with PMS exhibited less sedation and less decrease in saccadic eye velocity (SEV) compared with controls in response to i.v. diazepam, sedation and less decrease in saccadic eye velocity (41) noted that women with PMS exhibited less be more pronounced in women with PMS. Sundstrom et al. (41) noted that women with PMS exhibited less sedation and less decrease in saccadic eye velocity (SEV) compared with controls in response to i.v. diazepam, sedation and less decrease in saccadic eye velocity (41) noted that women with PMS exhibited less sedation and less decrease in saccadic eye velocity (SEV) compared with controls in response to i.v. diazepam, sedation and less decrease in saccadic eye velocity (SEV)

THDOC is another metabolite of progesterone and corticosterone, which is produced in the periphery in the adrenal gland. After acute stress, the circulating concentration of this hormone, in addition to those of pregnenolone and allopregnanolone, are increased (15–17). Serotonin increases ACTH secretion and this could in part represent a mechanism whereby allopregnanolone derived from the adrenal gland could increase after 1-TP challenge (45). However, in our study, after 1-TP administration the circulating concentration of allopregnanolone but not of THDOC or pregnenolone was increased. This strongly indicates that the increase in allopregnanolone concentration after 1-TP administration in the current study was probably due to some specific effect of 1-TP, rather than due to non-specific effects of acute stress.

This study is a preliminary report and has certain limitations, therefore the results should therefore be interpreted with caution. In this study we have measured peripheral circulating concentrations of neuroactive steroids and assumed a relationship with the concentration of the hormones in the brain. However, some, but not all, studies in rodents do indicate some interrelationship between peripheral concentrations of these hormones, especially progesterone and allopregnanolone, with those in the brain (46–48).

Our study did not examine the mechanism by which 1-TP administration led to an increase in the circulating concentrations of allopregnanolone. It has been postulated by other investigators that the SSRIs fluoxetine and paroxetine increase allopregnanolone concentrations by a complex interaction of these compounds with 3α-hydroxysteroid oxidoreductase, one of the two enzymes involved in the metabolism of progesterone to allopregnanolone, thus modulating the activity of this enzyme. Authors of another study, however, concluded that the anticonvulsant action of fluoxetine was due to enhanced synaptic action of endogenous 5-hydroxytryptamine (49). Our present findings also suggest the possibility that the effects on allopregnanolone observed with SSRIs may be at least in part due to enhanced central serogeneric activity, and not solely due to specific interaction of the SSRI with the 3α-hydroxysteroid oxidoreductase enzyme.

In conclusion, our studies indicate for the first time a positive relationship between the administration of 1-TP and plasma allopregnanolone concentrations. This is most probably due to an increase in central serotonergic tone and may potentially explain, at least in part, some of the effects observed in women with PMS treated with serotonergic agonists. Further studies are in progress, measuring the neurosteroid concentrations in CSF and correlating them with those in the peripheral circulation in women with PMS and controls and determining whether these concentrations change after modulation of central serotonergic tone.


12 Endicott J, Nee J, Cohen J & Halbreich H. Premenstrual changes

13 Barbaccia ML, Concas A, Serra M & Biggio G. Stress and

14 Griffin LD & Mellon SH. Selective serotonin reuptake inhibitors

15 Uzunov DP, Cooper TB, Costa E & Guidotti A. Fluoxetine-elicited


24 Sundblad C, Hedberg MA & Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. *Neuropsychopharmacology* 9 133–145.


29 Sundblad C, Hedberg MA & Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. *Neuropsychopharmacology* 9 133–145.


40 Sundblad C, Hedberg MA & Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. *Neuropsychopharmacology* 9 133–145.


42 Sundblad C, Hedberg MA & Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. *Neuropsychopharmacology* 9 133–145.


45 Sundblad C, Hedberg MA & Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. *Neuropsychopharmacology* 9 133–145.

46 Sundblad C, Hedberg MA & Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo controlled trial. *Neuropsychopharmacology* 9 133–145.


Received 5 September 2000
Accepted 2 February 2001